Intention-to-treat analysis
SUPERINFECTION
No significant difference was observed in the 14-day clinical response between the HD and LD groups in the intention-to-treat analysis. 95/152 (62.5%) patients in the HD group and 95/159 (59.7%) patients in the LD group met the criteria for clinical response (risk difference [RD], 2.75%; relative risk [RR]: 1.046; 95% confidence interval [CI]: 0.876–1.249; Outcomes for intention-to-treat populationData are n (%) or median (IQR). n: sample size. HD: high dose. LD: low dose. RR: relative risk. HR: hazard ratio. RD: risk difference. *: Superinfection and original Bacterial persistence co-exist in 6 patients, so the sum of the parts of bacterial clearance is greater than 100% #: Ventilated-free days at 28 days. †: Length of ICU stay. ‡: Length of hospital stayAlso, no significant difference was detected in all-cause mortality at 14 or 28 days after randomization. The 14-day mortality rate of the HD and LD groups was 23.7% (36/152) and 27.7% (44/159), respectively, and the RD was − 3.99% (95% CI − 13.57% to 5.74%). The 28-day mortality rate was 30.9% (47/152) and 37.7% (60/159) in the HD and LD groups, respectively (RD: − 6.8%, 95% CI − 17.12% to 3.73%). Subsequently, 25 (16.4%) patients in the HD group and 15 (9.4%) patients in the LD group were discharged from the hospital on day 28 after randomization (Table Kaplan–Meier’s survival curve of 180 days